As global head of product development at Sandoz, a Novartis division, Dr. Deshmukh leads a team of 1000+ associates to carry out integrated product development for pharmaceuticals. He oversees the strategy, performance and capability building for R&D teams including technical, clinical, medical and regulatory domains. Dr. Deshmukh also oversees the product investment strategy as a member of the Sandoz Executive Committee.
In his 20+ years in pharmaceutical R&D he has contributed over fifty lectures/publications, patents and brought to market multiple life saving medicines. He helped pioneer Quality by Design as part of the US FDA’s pilot program for regulatory approval of Torisel®. In 2019 his team helped Sandoz become the first multinational Pharma to get approval for a Quality Certificate of Excellence (QCE) generic in China. He is actively shaping in-silico R&D through adoption of modeling, simulation and remote sensing solutions.
Prior to joining Novartis in 2016, Dr. Deshmukh was Senior Vice President of R&D at Sun Pharma and earlier served in roles at Pfizer/Wyeth including as Head of US Materials Science and Senior Director for Technology Operations. His training includes a Ph.D. in Chemical Engineering as Aristech Foundation Fellow from the University of Pittsburgh. He also holds an MBA with honors from the Wharton School, University of Pennsylvania.